(800) 943-6396

150 Essex St, Millburn, NJ 07041, USA

©2019 by Bon Opus Biosciences, LLC.

S100A4 Recombinant Rabbit monoclonal Antibody IgG

SKU: BA111810-100µl
$279.00Price

Fig1: ICC staining S100A4 in NIH/3T3 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.

Fig2: ICC staining S100A4 in Hela cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.

Fig3: ICC staining S100A4 in MCF-7 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.

Bon Opus Cat. #BA111810
Size
  • Host Species; Species Reactivity

    Rabbit; Human, Mouse, Rat
  • Immunogen

    Recombinant protein
  • Application Summary

    WB, ICC/IF, IHC, IP, FC
  • Purification; Formulation

    ProA affinity purified; 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.; Liquid form.
  • ALTnames

    Protein S100-A4, Calvasculin, Metastasin, Placental calcium-binding protein, Protein Mts1, S100 calcium-binding protein A4
  • Background

    The Mts1 gene encodes a small acidic Ca2+-binding protein, Mts1 (also designated S100A4, calvasculin or metastasin). Mts1 belongs to the S100 family of small Ca2+-binding proteins and is expressed in a cell-specific manner. Mts1 protein is involved in tumor progression and metastasis, and also has a significant stimulatory effect on angiogenesis. The level of Mts1 protein in serum increases with aging, suggesting that Mts1 may play a role in the ind-uction of tumor progression via stimulation of angiogenesis. In addition, Mts1 cooperates with p53 in apoptosis induction by binding to the C-term-inal regulatory domain of p53 to inhibit the DNA binding activity of p53. The ability of Mts1 to enhance p53-dependent apoptosis may accelerate the loss of p53 function in tumors. Thus, Mts1 can contribute to the development of a more aggressive phenotype during tumor progression.(ET1612-13)